Inhibiting the phosphoinositide 3-kinase pathway for cancer treatment. (1st April 2004)

• Record Type: Journal Article
• Authors: Workman, P.
• Is Part Of: Biochemical Society transactions. Volume 32:Number 2(2004)
• Page Start: 393
• Page End: 396
• Publication Date: 2004-04-01
• Subjects: cancer -- isoform-selective inhibitor -- phosphoinositide 3-kinase (PI 3-kinase) -- small-molecule inhibitor; Biochemistry -- Congresses; 572
• DOI: 10.1042/bst0320393
• Languages: English
• ISSNs: 0300-5127

Abstract

Abstract : There is extensive evidence from the molecular and genomic analysis of human cancers that the PI 3-kinase (phosphoinositide 3-kinase)–Akt/PKB (protein kinase B) pathway is deregulated in malignant progression. Furthermore, the causal involvement of PI 3-kinase is supported by gene-knockout mouse models. Prototype inhibitors show evidence of anticancer activity in vitro and in vivo animal models. The recent development of isoform-selective inhibitors shows considerable promise for cancer treatment.